Patient Support across our Therapeutic Areas

Diabetes

Dyslipidaemia

Neurology

Oncology

Rare Blood Disorders

Rare Diseases

Thrombosis

Vaccines

Supporting your Patients

Articles and materials to support your patients’ needs

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

Our Products

ADMELOG
insulin lispro

Prescribing Information GB
GB ONLY CONTENT

MAT-GB-2105789 (v6.0)
Date of preparation: February 2023

ALDURAZYME
laronidase

Prescribing Information GB
Prescribing Information NI

 

MAT-XU-2200954 (v2.0)
Date of preparation: February 2023

AUBAGIO
teriflunomide

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200676 (v4.0)
Date of preparation: April 2023

AVAXIM® Junior

Prescribing Information UK

MAT-XU-2301296 (v1.0)
Date of preparation: April 2023

AVAXIM®

Prescribing Information UK

MAT-XU-2301117 (v1.0)
Date of preparation: April 2023

Cablivi
caplacizumab

Prescribing Information GB
Prescribing Information NI

 

MAT-GB-2105168 (v5.0)
Date of preparation: May 2023

CERDELGA
eliglustat 84mg

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204064 (v2.0)
Date of preparation: January 2023

CEREZYME
imiglucerase

Prescribing Information GB
Prescribing Information NI

 

MAT-XU-2204065 (v2.0)
Date of preparation: January 2023


Clexane
enoxaparin


Prescribing Information UK

MAT-XU-2204397 (v2.0)
Date of preparation: May 2023

Fabrazyme
agalsidase beta

Prescribing Information GB
Prescribing Information NI

 

MAT-GB-2105812 (v4.0)
Date of preparation: May 2023

LANTUS
insulin glargine

Prescribing Information GB
Prescribing Information NI

MAT-XU-2201444 (v3.0)
Date of preparation: January 2023

LEMTRADA
Alemtuzumab

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200680 (v2.0)
Date of preparation: August 2022

 

 

Prescribing Information GB
Prescribing Information NI

 

MAT-XU-2202651 (v1.0)
Date of preparation: February 2023

MenquadfiTM

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301129 (v1.0)
Date of preparation: May 2023

MYOZYME
alglucosidase alfa

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105179 (v3.0)
Date of preparation: February 2023

NEXVIADYME
avalglucosidase alfa

Prescribing Information GB
GB ONLY CONTENT

 

MAT-XU-2203480 (v3.0)
Date of preparation: February 2023

PRALUENT
alirocumab


Prescribing Information GB
Prescribing Information NI

 

MAT-XU-2204604 (v2.0)
Date of preparation: March 2023

QIV®

Prescribing Information UK

MAT-XU-2301127 (v1.0)
Date of preparation: May 2023

REPEVAX®

Prescribing Information UK

MAT-XU-2301125 (v1.0)
Date of preparation: May 2023

REVAXIS®

Prescribing Information UK

MAT-XU-2301123 (v1.0)
Date of preparation: May 2023

REZUROCK
belumosudil tablets

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2202695 (v2.0)
Date of preparation: April 2023

SARCLISA
isatuximab

Prescribing Information GB
GB ONLY CONTENT

 

MAT-XU-2202578 (v1.0)
Date of preparation: May 2023

STAMARiL®

Prescribing Information UK

MAT-XU-2301130 (v1.0)
Date of preparation: May 2023

Supemtek®

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301126 (v1.0)
Date of preparation: May 2023

TOUJEO
insulin glargine

Prescribing Information UK

MAT-GB-2105435 (v7.0)
Date of preparation: May 2023

TRURAPI
insulin aspart

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2205461 (v6.0)
Date of preparation: April 2023

TYPHIM Vi®

Prescribing Information UK

MAT-XU-2301128 (v1.0)
Date of preparation: May 2023

VAXELIS®

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301124 (v1.0)
Date of preparation: May 2023

▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.

MAT-XU-2301218 (v2.0)
Date of preparation: May 2023